{"product_id":"exelixis-five-forces-analysis","title":"Exelixis Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExelixis faces intense rivalry from established oncology peers, high buyer scrutiny from payers and providers, and moderate supplier power tied to specialty manufacturing; patent portfolios and clinical pipeline shape barriers to entry and substitute threats. This snapshot highlights strategic pressures on pricing, R\u0026amp;D priorities, and partnership choices.\u003c\/p\u003e\n\u003cp\u003eThis preview is just the beginning. The full Porter's Five Forces Analysis provides force-by-force ratings, visuals, and business implications tailored to Exelixis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated specialty CMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis depends on a limited pool of GMP-qualified CMOs for small-molecule APIs and finished doses, concentrating supplier power and raising switching costs, validation burdens, and lead-time risk. Long-term agreements reduce supply risk but can lock in vendor pricing power. Dual-sourcing and inventory buffers partially mitigate disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiologics and assay dependencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunotherapy workstreams for Exelixis depend on specialized biologics, assays and companion diagnostics where only a handful of validated providers meet 2024 regulatory and commercial quality standards; this consolidation raises supplier leverage. Lead times and complex tech transfers extend timelines and increase switching costs, giving suppliers negotiating advantage. Co-development of diagnostics often creates supplier lock-in through proprietary assays and data sharing arrangements.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCROs and clinical site capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D for Exelixis relies heavily on CROs and high-performing oncology sites, with the global CRO market reaching about $64 billion in 2024 and oncology representing roughly 30% of trial volume, creating concentrated demand for limited site capacity.\u003c\/p\u003e\n\u003cp\u003eCompeting sponsors vie for the same investigators and patients, pushing site fees and per-patient costs up—site activation now often takes 90–120 days—so performance-based contracts mitigate but do not eliminate bottlenecks.\u003c\/p\u003e\n\u003cp\u003eGeographic diversification across North America, Europe and select APAC centers reduces enrollment risk and shortens median enrollment timelines by improving patient access and investigator availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary platform\/tool vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to niche discovery tools, bioinformatics and cell models often requires proprietary licenses (Illumina held ~70% NGS market share in 2024), creating vendor uniqueness and data lock-in that raise dependency and switching costs.\u003c\/p\u003e\n\u003cp\u003eNegotiating broad-use rights can be costly; reliance on AWS (≈33% cloud IaaS share in 2024) or specialized vendors increases bargaining power, while building internal capabilities reduces dependence but needs sustained R\u0026amp;D investment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eHigh vendor concentration: Illumina ≈70% (2024)\u003c\/li\u003e\n\u003cli\u003eCloud reliance: AWS ≈33% IaaS (2024)\u003c\/li\u003e\n\u003cli\u003eLicensing raises costs; internal build requires ongoing R\u0026amp;D spend\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulated quality and compliance costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulated quality shifts validation burdens onto Exelixis suppliers, who pass through higher compliance costs into contracts; audit findings often force remediation or requalification, delaying programs and reprioritizing production schedules.\u003c\/p\u003e\n\u003cp\u003ePreferred-supplier status improves priority but brings higher baseline pricing; rigorous quality-by-design narrows acceptable vendor alternatives, concentrating supplier power and raising switching costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSuppliers absorb validation then pass costs\u003c\/li\u003e\n\u003cli\u003eAudits can trigger remediation and delays\u003c\/li\u003e\n\u003cli\u003ePreferred status = higher price, faster priority\u003c\/li\u003e\n\u003cli\u003eQuality-by-design shrinks vendor pool\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier concentration in GMP CMOs, CROs and diagnostics amplifies pricing and timing leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh supplier concentration for GMP CMOs, CROs and diagnostics gives suppliers pricing and timing leverage over Exelixis.\u003c\/p\u003e\n\u003cp\u003eCRO market ≈$64B (2024) with oncology ≈30% increases site\/capacity pressure and costs.\u003c\/p\u003e\n\u003cp\u003eKey vendors: Illumina ≈70% NGS share (2024); AWS ≈33% IaaS (2024) — raises lock-in and switching costs.\u003c\/p\u003e\n\u003cp\u003eLong-term contracts reduce disruption risk but preserve supplier pricing power.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO market\u003c\/td\u003e\n\u003ctd\u003e$64B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology share\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIllumina NGS\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAWS IaaS\u003c\/td\u003e\n\u003ctd\u003e~33%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for Exelixis that uncovers competitive intensity, buyer\/supplier power, threat of substitutes and new entrants, and highlights disruptive forces and market dynamics shaping its profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-sheet Porter's Five Forces for Exelixis that distills competitive pressures into a radar chart for instant strategic clarity, with editable pressure levels and labels to model scenarios (e.g., new drug entrants or regulatory shifts) and no macros—ready to drop into decks or Excel dashboards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and PBMs’ formulary control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUS payers and PBMs exert outsized leverage over oncology pricing and access, with the three largest PBMs covering roughly 70–80% of prescription drug lives, enabling broad use of step therapy, prior authorization, and rebate-driven formulary placement that compresses Exelixis’s net price realization. Robust overall survival or quality-of-life data for a drug reduces buyer bargaining power by increasing clinical indispensability. Value-based contracts can align incentives but typically limit upside by linking payment to outcomes and sharing risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncologist and center-of-excellence influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrescribing in oncology is concentrated among specialists at leading centers—there are 72 NCI-designated cancer centers in 2024 that drive referral patterns and adoption. KOL preferences and guideline inclusion meaningfully steer uptake, often determining formulary placement and prescribing habits. Differentiated efficacy in defined subpopulations reduces buyer sensitivity by creating niche demand. Real-world outcomes can reinforce or erode physician leverage through post-marketing effectiveness signals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational HTA and tender pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEx-US markets rely on HTA bodies and national tenders to set drug prices, with tenders often producing double-digit discounts (commonly 20–60%) and reference pricing used by over 50 countries, intensifying buyer leverage. Budget caps and affordability thresholds force payers to limit uptake; demonstrable cost-effectiveness is essential to defend value. Local commercial partners ease access but share pricing and margins, reducing Exelixis net revenue per region.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and access programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy and access programs push for broader, affordable access to Exelixis therapies; co-pay support and free-drug programs ease patient resistance but compress net revenues, while strong safety data for Cabometyx and other agents supports price retention; higher toxicity increases bargaining for discounts or switches to lower-toxicity alternatives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient groups: broader access and affordability\u003c\/li\u003e\n\u003cli\u003eAssistance programs: lower patient costs, reduce net revenue\u003c\/li\u003e\n\u003cli\u003eSafety profile: enables higher pricing\u003c\/li\u003e\n\u003cli\u003eToxicity: drives discount demands or therapy substitution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvailability of therapeutic alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvailability of multiple approved first-line combos (three major competing regimens in metastatic RCC as of 2024) strengthens buyer negotiating leverage over Exelixis on price and formulary placement; cabozantinib (Cabometyx) retains countervailing power through unique VEGFR\/MET\/AXL inhibition and demonstrated combo synergies with nivolumab that reduce direct substitutability. Label breadth across RCC, HCC and differentiated thyroid cancer expands placement options, but post-patent generic entry typically shifts pricing power decisively to buyers, often causing innovators to face steep price erosion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThree major 1L RCC combos (2024)\u003c\/li\u003e\n\u003cli\u003eCabozantinib approved in RCC, HCC, DTC\u003c\/li\u003e\n\u003cli\u003eUnique mechanism + nivolumab synergy lowers substitutability\u003c\/li\u003e\n\u003cli\u003ePost-patent generic entry often triggers substantial price erosion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTop-3 PBMs drive \u003cstrong\u003e~75%\u003c\/strong\u003e drug lives; ex-US tenders cut prices \u003cstrong\u003e20-60%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTop-3 US PBMs cover ~75% of drug lives in 2024, using rebates\/step therapy that compress Exelixis net price. HTA bodies and tenders drive 20–60% discounts ex‑US; reference pricing used by 50+ countries. Strong OS\/QoL data and label breadth (RCC, HCC, DTC) reduce buyer leverage, but post‑patent generics trigger steep price erosion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop‑3 PBM share\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003ctd\u003eHigh pricing pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx‑US tender discounts\u003c\/td\u003e\n\u003ctd\u003e20–60%\u003c\/td\u003e\n\u003ctd\u003eRevenue reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eExelixis Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Exelixis Porter’s Five Forces analysis you’ll receive—fully written, formatted, and ready for use. No placeholders, mockups, or truncated samples are included. Purchase grants immediate access to this identical file for download. What you see here is the final deliverable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162956312953,"sku":"exelixis-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/exelixis-five-forces-analysis.png?v=1762712005","url":"https:\/\/portersfiveforce.com\/products\/exelixis-five-forces-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}